News

We send the latest information from SMC Laboratories.

2021.04.09

NEWS RELEASE

Wnt/β-catenin in our NASH-HCC model: How does it correlate to human liver cancer?

The main cause of hepatocellular carcinogenesis today is chronic liver disease following HCV and HBV infection…

READ MORE

2021.04.02

NEWS RELEASE

CohBar, Inc. announces the completion of enrolment in the Phase 1b stage of the CB4211 clinical study of NASH and obesiy.

CohBar, Inc. (USA) announced on March 29, 2021, that the completion of enrolment in the Phase 1b stage of the …

READ MORE

2021.03.04

PRODUCTS AND SERVICE

Positive control for UUO kidney fibrosis

We are excited to share with you an update about a newly established positive control – an ALK5 inhibito…

READ MORE

2021.02.22

NEWS RELEASE

Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-b Agonist ASC41

Gannex (Shanghai, China) has announced positive clinical results in overweigth and obse subjects for its THR-b…

READ MORE

2021.02.15

NEWS RELEASE

TERNS announces FDA clearance of investigational new drug application for first-in-human phase 1 trial of TERN-501, its THR-beta agonist in development for the treatment of NASH

TERNS Pharmaceuticals, Inc. (USA) has announced FDA clearance of investigational new drug aplication for first…

READ MORE

2021.02.04

NEWS RELEASE

Inventiva announces design of Phase III clinical trial with Ianifibranor in NASH

Inventiva (France) has announced design of Phase III clinical trial with Ianifibranor in NASH   For detai…

READ MORE

2021.01.22

NEWS RELEASE

Hepion pharma announces positive top line data for low dose CRV431 in Phase 2a "AMBITION' clinical trial for treatment of advanced NASH.

Hepion pharma (NJ), which is our client, has announced positive top line data for low dose CRV431 in Phase 2a …

READ MORE

2021.01.14

NEWS RELEASE

Lipocine announces positive topline Phase 2 results from LPCN1144 ongoing Lift study in biopsy-confirmed NASH subjects

Lipocine (USA, UA) announced on 12 January, 2021, positive topline Phase 2 results from LPCN1144 ongoing LiFT …

READ MORE

2021.01.08

NEWS RELEASE

Chemomab announces positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients

Chemomab Ltd.(Israel) announced on 5 January, 2021, positive Phase Ib results of its SPARK study testing CM-10…

READ MORE

2020.12.18

NEWS RELEASE

Can-Fite reports on progress with its Namodenoson NASH program

Can-Fite (Israel) reports on 14 December, 2020, on progress with its Namodenoson NASH program.   For deta…

READ MORE

Page 15 of 20First1314151617Last